Redplate has a new gig.
TapImmune Appoints Mark Reddish to Its Management Team as Vice President Product Development
Former Executive at ID Biomedical and Biomira Inc Brings Broad Experience and Expertise in Cancer and Biodefense Product Development
Mark was far to young and mentally active to retire to the golf course.
It is interesting that his work should be in the field that he was challenged by two posters here.
Such is life.
>>It is interesting that his work should be in the field that he was challenged by two posters here.<<
Has someone been challenging Redplate’s work in product development?
Redplate has earned my grief because of his constant lying that makes this investment look rosier than is deserved and his antiquated understanding of T cell assays. Remember his story that the 20% positive immune response in the phase II trial shouldn’t be believed because when the same exact assays were performed immediately during a phase I study the response was 13/17? Then we found out the 17 patients were healthy normals and the therapy was given ex-vivo. What a dunce. And when arguing against IFN-gamma ELISPOT we got, “killer cells kill.” What a simpleton.
So no walshingham07, working for another podunk btech isn’t going to impress me. Just as little can be made from GSK not wanting him around and his not earning a PhD.
Hope the Red Head packs a sustaining lunch box.
Hope the new office has an after lunch thinking couch for contemplation in the horizontal position.
Pick an ugly secretary you do not want your hide nailed to the barn door by the Red Head.
"The intellectual property rights developed by Dr. Antoine A. Noujaim and Dr. B. Michael Longenecker were licensed to Biomira in 1986. It’s been 25 years already."
The IP you mention has no relationship to the IP and development that underlies Stimuvax.
>> So Dr Butts and Red are both misguided.<<
Dr. Butts and redplate have said different things. Redplate believes T cells die if you they are isolated after overnight shipping and cites his patent from 2000 as evidence. If this were true wouldn’t there have been some movement in that direction over the last decade? The opposite has happened. Nearly all clinical samples are shipped to the sponsor for testing prior to processing.
Dr. Butts on the other hand as only said there is a possibility that the samples may have been compromised during the handling and shipping for this particular study. He didn’t make a global statement about shipping T cells generally.
Butts speculated without any data support. That’s not good but allowed if only done occasionally. Redplate has made factually incorrect statements. This is a much graver error.
Looking at Martin's biography, besides being a self proclaimed philanthropist, he appears to have completed High School or at least got a GED. There is no statement of obtaining a college degree from my recollection,just an "he attended" mention.I think he is busy with his buyout efforts and keeping his well educated daughter in line.She may be "going native" here. Getting beaten down. Maybe a case of the Stockholm Syndrome.
Hey zanghia, congrats on VRUS.
Not sure why you'd need to conclude that ONTY was a dud, though.
Feels like your timing is splendiferous.
Why wouldn't you want to double up now? This thing is on a short fuse!